Nutrition Intervention During Chemotherapy

This study is currently recruiting participants.
Verified January 2014 by Texas A&M University
Sponsor:
Information provided by (Responsible Party):
Marielle PKJ Engelen, PhD, Texas A&M University
ClinicalTrials.gov Identifier:
NCT01871350
First received: June 4, 2013
Last updated: January 10, 2014
Last verified: January 2014
  Purpose

Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival. Weight loss has been reported as a side effect of chemotherapy treatment in cancer. Weight changes may be the consequence of energy imbalance and disturbances in protein metabolism (through different factors linked with chemotherapy), such as reduced caloric and protein intake (partly related to depression), poor treatment tolerance, hormonal alterations, systemic inflammation etc. This results in body composition modifications in favor of fat gain and/or lean body mass loss in early stage cancer and loss of both fat mass and lean mass in advanced cancer. Depletion of lean tissue in cancer patients is related to short survival, and decreased skeletal muscle mass and function may result in fatigue and inactivity, which contributes to fat mass changes and can be responsible for chemo-toxicity and increased mortality.

Gains in muscle mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. Recently, the investigators observed that essential amino acid mixtures (EAA) are able to induce protein anabolism in patients with stage III and IV non-small cell lung cancer. Previous experimental research and clinical studies in cachectic conditions (including cancer) indicate that polyunsaturated fatty acids (PUFA) are able to attenuate protein degradation by improving the anabolic response to feeding and by decreasing the acute phase response. Eicosapentaenoic acid (EPA) (in combination with docosahexaenoic acid (DHA)) has been shown to effectively inhibit weight loss in several disease states; however, weight and muscle mass gain was not present or minimal. Recent studies examining the effect of fish oil supplementation in relation to chemotherapy have been inconclusive but found potential beneficial effects on physical performance and increased efficacy of first-line chemotherapy in patients with non-small cell lung cancer.

It is the investigators' hypothesis that supplementation with casein hydrolysate (containing essential amino acids) carbohydrate (CHO) mixture in combination with fish oil supplementation will target the metabolic alterations in cancer patients receiving chemotherapy, attenuating the negative effects of chemotherapy on gut function, muscle mass and muscle function, and cognition; and leading to reduced toxicity from chemotherapy.


Condition Intervention
Cancer Patients Receiving Platinum-based Chemotherapy
Dietary Supplement: Daily intake for 12 weeks

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Supportive Care
Official Title: Effects of Chemotherapy and Nutritional Intervention on Gut Function and Metabolism in Cancer

Resource links provided by NLM:


Further study details as provided by Texas A&M University:

Primary Outcome Measures:
  • Net whole-body protein synthesis [ Time Frame: Acutely before and after 4 hours of feeding and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    The acute change in whole-body protein synthesis rate before and after intake of meal is determined on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.


Secondary Outcome Measures:
  • Citrulline Rate of appearance [ Time Frame: In the postabsorptive state for 4h on the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Plasma enrichment of citrulline is determined on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Glucose absorption [ Time Frame: 7 hours during the test day and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Recovery of 3-O-Methyl-D-glucose in the urine is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Gut permeability [ Time Frame: 7 hours during the test day and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Recovery of rhamnose/lactulose in urine is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Skeletal and respiratory muscle strength [ Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Difference in leg strength and fatigue, handgrip strength and fatigue, and inspiratory and expiratory pressure between heart failure patients and healthy controls on test day 1. The cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Cognitive function [ Time Frame: On the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Outcome of neuro-psychological tests in heart failure patients and healthy controls in relation to the tryptophan metabolism. The cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Fatty acid digestion after feeding [ Time Frame: Acutely after 4 hours of feeding and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Enrichment in palmitic acid and tripalmitin fatty acids in plasma in response to a meal is measured on the first test day in for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Protein digestion after feeding [ Time Frame: Acutely after 4 hours of feeding and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Ratio enrichment free phenylalanine vs phenylalanine from protein spirulina in response to a meal is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Whole body collagen breakdown rate [ Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Hydroxyproline enrichment in plasma is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Tryptophan turnover rate [ Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Tryptophan enrichment in plasma is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Insulin response to feeding [ Time Frame: Before and acutely after 4 hours of feeding and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    The acute change in insulin levels before and after intake of meal is determined on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Fat-free mass [ Time Frame: In postabsorptive state on test day 1 and the difference on test day 2, after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Fat free mass is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Myofibrillar protein breakdown rate [ Time Frame: Before and acutely after 4 hours of feeding and the change after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    The acute change 3-methylhistidine enrichment in plasma before and after intake of meal is determined on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Glycine rate of appearance [ Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Glycine enrichment in plasma is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.

  • Taurine turnover rate [ Time Frame: In the postabsorptive state on the first test day and the change on the second test day after 12 weeks of supplementation ] [ Designated as safety issue: No ]
    Enrichment of taurine in plasma is measured on the first test day for the healthy control group and the cancer group. Secondly, the cancer patients in all 3 intervention arms are also measured after 12 weeks of intervention to examine the effects of fish oil and protein supplementation during chemotherapy on this outcome measure.


Estimated Enrollment: 91
Study Start Date: April 2013
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Protein and Fish Oil

Low Dose (FFM <49kg): 30g hydrolyzed casein + 12.75g maltodextrin and 6g fish oil

High dose (FFM >49kg): 40g hydrolyzed casein + 17.00g maltodextrin and 8g fish oil

Dietary Supplement: Daily intake for 12 weeks
Experimental: Protein

Low Dose (FFM <49kg): 30.0g hydrolyzed casein + 12.75g maltodextrin and 6g olive oil

High dose (FFM >49kg): 40.0g hydrolyzed casein + 17.00g maltodextrin and 8g olive oil

Dietary Supplement: Daily intake for 12 weeks
Placebo Comparator: Placebo

Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil

High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil

Dietary Supplement: Daily intake for 12 weeks

Detailed Description:

For the cancer subjects, the study involves 1 test day (approx. 8 hours) before chemotherapy, an approximately 12-week intervention at home starting the first day of chemotherapy, and one test day after this intervention. A common treatment plan for the platinum-based chemo is four doses with 3 week intervals and a clinical evaluation after these 12 weeks. Cancer subjects will be randomly assigned to receiver either fish oil or a placebo and protein or a placebo and will take these supplements daily throughout those 12 weeks.

For the healthy subjects, the study will involve one test day (approx. 8 hours)

On these test days, the response to a protein meal will be examined and subjects will receive a mixture of amino acids which are a little bit heavier than normal, called stable isotopes. Subjects will also ingest a sugar drink to assess gut permeability. In total, approximate 120 ml of blood will be drawn on each test day to assess outcome measures. The investigators' will also collect urine over these 8 hours, and cancer subjects are asked to collect a fecal sample the day before the test day.

  Eligibility

Ages Eligible for Study:   25 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria cancer subjects:

  • Recently diagnosed with cancer
  • Will receive platinum-based chemotherapy
  • Ability to sign informed consent
  • Age 25y and older
  • Ability to lie in supine position for 7 hours

Inclusion criteria healthy subjects:

  • Healthy male or female according to the investigator's or appointed staff's judgment
  • Age 45 years or older
  • No diagnosis of cancer

Exclusion Criteria

  • Presence of fever within the last 3 days
  • BMI > 38 kg/m2 (healthy controls only)
  • Untreated metabolic diseases including hepatic or renal disorder
  • Presence of acute illness or metabolically unstable chronic illness
  • Use of protein or amino acid containing nutritional supplements within 5 days of first test day
  • Known hypersensitivity to fish and/or shellfish, Swanson EFAs Super EPA Fish oil or any of its ingredients, Swanson EFAs Certified Organic Extra Virgin Olive oil or any of its ingredients (Cancer subjects only)
  • Use of supplements containing EPA+DHA 3 months prior to the first test day
  • Any other condition according to the PI or nurse that would interfere with the study or safety of the patient
  • Failure to give informed consent
  • (Possible) pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01871350

Contacts
Contact: Marielle PKJ Engelen, PhD 9792202282 mpkj.engelen@ctral.org

Locations
United States, Texas
Texas A&M University Recruiting
College Station, Texas, United States, 77843
Contact: Marielle PKJ Engelen, PhD    9792202282    mpkj.engelen@ctral.org   
Sponsors and Collaborators
Texas A&M University
Investigators
Principal Investigator: Marielle PKJ Engelen, PhD Texas A&M Univeristy
  More Information

No publications provided

Responsible Party: Marielle PKJ Engelen, PhD, PhD, Texas A&M University
ClinicalTrials.gov Identifier: NCT01871350     History of Changes
Other Study ID Numbers: 2012-0504
Study First Received: June 4, 2013
Last Updated: January 10, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Texas A&M University:
Cancer
Chemotherapy
Chemo related toxicity
Protein digestion
Fat digestion
Gut function
Glucose absorption
Muscle function

ClinicalTrials.gov processed this record on April 17, 2014